Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Matteo Silberg

Showing results (1-10 of 3) with videos related to

Pageof 1
Sort By:
Clinical Genitourinary Cancer|August 17, 2024
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsMatteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
Urologia Internationalis|February 25, 2025
Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?Henning Bahlburg, Patricia Rausch, Matteo Silberg, et al.
International Journal of Cancer|November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS groupHendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
Pageof 1

Showing results (1-10 of 3) with videos related to

Sort By:
Pageof 1
Clinical Genitourinary Cancer|August 17, 2024
Immune-Related Adverse Events Can Predict Progression-Free and Overall Survival In Patients With Metastatic Renal Cell Carcinoma Treated With Immune Checkpoint InhibitorsMatteo Silberg, Laura-Maria Krabbe, Martin Bögemann, et al.
Urologia Internationalis|February 25, 2025
Stage Migration in Urological Cancers in Germany during the COVID-19 Pandemic: Fact or Fiction?Henning Bahlburg, Patricia Rausch, Matteo Silberg, et al.
International Journal of Cancer|November 29, 2025
Real-world efficacy and toxicity of ipilimumab and nivolumab as a first-line treatment for advanced renal cell carcinoma according to IMDC risk criteria-A multi-center retrospective analysis on behalf of the GUARDIANS groupHendrik Dinkel, Linus Materna, Ramona Stelmach, et al.
Pageof 1